CRISPR Therapeutics AG
CRSP- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001674416
In the last 90 days, CRISPR Therapeutics AG insiders filed 0 open-market purchases and 2 sales; 525 institutions reported holding it in 13F filings for Q2 2026, worth $4.16B in total; ARK Invest is the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding CRISPR Therapeutics AG changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 436 | 8 | 399 | −29 |
| Shares | 56.7M | 73.4K | 55.5M | −1.10M (−1.9%) |
| Value | $3.70B | $4.79M | $2.26B | −$1.44B (−39.0%) |
8 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (57)
Institutions that held CRISPR Therapeutics AG at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (86)
Institutions that held CRISPR Therapeutics AG at the end of Q3 2022 and filed for Q4 2022 without it.
Not filed for Q4 2022 yet (8)
Institutions that held CRISPR Therapeutics AG at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| AGF Investments LLC | 25,111 | $1.64M |
| American Portfolios Advisors | 20,785 | $1.36M |
| Eaton Vance Management | 20,413 | $1.33M |
| Bluestein R H & Co | 5,700 | $372.0K |
| Wipfli Financial Advisors LLC, | 630 | $41.0K |
| Covington Capital Management | 495 | $32.0K |
| FourThought Financial, LLC | 164 | $11.0K |
| Pacific Center for Financial Services | 81 | $5.00K |